Sunshine Biopharma Inc
SBFMW0.288USD
-0.012-4.10%
Close 04/23, 16:00（ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
More Details of Sunshine Biopharma Inc Company
Sunshine Biopharma Inc. is a pharmaceutical company engaged in offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has approximately 70 generic prescription drugs on the market in Canada. In addition, the Company is conducting a proprietary drug development program which is comprised of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for the treatment of SARS Coronavirus infections. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). The Company operates two wholly owned subsidiaries: Nora Pharma Inc., which has a portfolio of pharmaceutical products consisting of various prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells nonprescription over-the-counter (OTC) products.
Company Info
Company codeSBFMW
Company nameSunshine Biopharma Inc
IPO dateAug 15, 2008
Founded at2006
CEODr. Steve N. Slilaty
Number of employees- -
Security typeCompany Warrant
Fiscal year-end- -
Address333 Las Olas Way
CityFORT LAUDERDALE
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code33301
Phone19545150810
Websitehttps://www.sunshinebiopharma.com/
Company codeSBFMW
IPO dateAug 15, 2008
Founded at2006
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Steve N. Slilaty
Dr. Steve N. Slilaty
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Mr. Malek Chamoun
Mr. Malek Chamoun
Chief Development Officer
Chief Development Officer
--
--
Dr. Andrew M. Keller
Dr. Andrew M. Keller
Independent Director
Independent Director
--
--
Dr. Rabi Kiderchah, M.D.
Dr. Rabi Kiderchah, M.D.
Independent Director
Independent Director
--
--
Mr. Marc Beaudoin
Mr. Marc Beaudoin
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Abderrazzak Merzouki
Dr. Abderrazzak Merzouki
Chief Science Officer, Director
Chief Science Officer, Director
--
--
Mr. David Natan
Mr. David Natan
Independent Director
Independent Director
--
--
Mr. Michel Roy
Mr. Michel Roy
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Camille Sebaaly
Mr. Camille Sebaaly
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Steve N. Slilaty
Dr. Steve N. Slilaty
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Mr. Malek Chamoun
Mr. Malek Chamoun
Chief Development Officer
Chief Development Officer
--
--
Dr. Andrew M. Keller
Dr. Andrew M. Keller
Independent Director
Independent Director
--
--
Dr. Rabi Kiderchah, M.D.
Dr. Rabi Kiderchah, M.D.
Independent Director
Independent Director
--
--
Mr. Marc Beaudoin
Mr. Marc Beaudoin
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Abderrazzak Merzouki
Dr. Abderrazzak Merzouki
Chief Science Officer, Director
Chief Science Officer, Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholder
Update time: Sun, Feb 23
Update time: Sun, Feb 23
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
Other
100.00%
Shareholder Statistics
Shareholder
Proportion
Other
100.00%
Type
Shareholder
Proportion
Other
100.00%
Institutional Shareholding
Update time: Tue, Mar 4
Update time: Tue, Mar 4
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
5
42.72K
0.00%
-18.68K
2024Q4
5
42.72K
0.00%
-18.68K
2024Q3
5
47.02K
0.00%
-38.45K
2024Q2
6
87.95K
0.00%
-8.56K
2024Q1
6
84.02K
0.00%
-7.28K
2023Q4
6
78.99K
0.00%
-17.09K
2023Q3
6
83.78K
0.00%
-60.47K
2023Q2
6
144.24K
0.00%
+102.73K
2023Q1
5
41.52K
0.00%
-13.18K
2022Q4
4
54.70K
0.00%
-15.25K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Citadel Advisors LLC
41.43K
0%
-3.70K
-8.20%
Dec 31, 2024
UBS Financial Services, Inc.
1.29K
0%
-600.00
-31.76%
Dec 31, 2024
Susquehanna International Group, LLP
--
0%
-12.30K
-100.00%
Sep 30, 2023
BofA Global Research (US)
--
0%
-200.00
-100.00%
Mar 31, 2024
Clear Street LLC
--
0%
-1.88K
-100.00%
Sep 30, 2024
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data